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Abstract
Low levels of both high density lipoprotein cholesterol (HDL) and cognitive function are associated with increased
mortality risk. HDL plays an important role in brain metabolism. We test the hypotheses that the relative protective
effect of high HDL level as related to mortality is greater in persons with impaired cognitive function than in
others. Data were analyzed from a longitudinal mortality follow-up study of 4911 American men and women aged
60 years and over examined in 1988-1994 followed an average 8.5 yr. Measurements at baseline included HDL, a
short index of cognitive function (SICF), socio-demographics, health status, and self-reported leisure-time physical
activity. In proportional hazards regression analysis, no significant interaction of HDL with cognitive function was
found (p = 0.08); there was a significant age-SICF interaction. After stratifying by age and adjusting for
confounding by multiple variables, independent associations of HDL and SICF score with survival were strongest
among the oldest persons. Consistent with its association with HDL, cognitive function and survival, controlling in
addition for physical activity reduced the associations. In a nationwide cohort of older Americans, analyses
demonstrated a lower risk of death independent of confounders among those high HDL and SICF scores, strongest
among the oldest persons.
Findings
Both low high-density lipoprotein cholesterol (HDL),
and impaired cognitive function are prevalent concomi-
tants of aging in industrialized nations [1,2]. Studies of
HDL and cognitive function and Alzheimer’s disease
suggest a possible negative association [3]. Recently
HDL has been found to play important roles in brain
pathophysiology [4-6]. Cognitive function has been
found to predict subsequent mortality in elderly adults
in a number of previous studies [7]. Mechanisms remain
obscure. High HDL has been found to be negatively
related to increased mortality from cardiovascular dis-
ease [8,9]. Mechanisms may include tissue cholesterol
removal, fibrinolytic activity, hemostatic function,
inflammation and oxidative stress leading to less athero-
sclerosis. However, information regarding interactions of
cognitive function and HDL cholesterol are lacking in
studies of mortality.
We test the hypothesis that the effect of HDL on mor-
tality is modified by cognitive function score, the effect
being less among those with high compared to those
with low scores. We analyzed available data from a
national health examination survey linked-mortality file
conducted with scientific sampling and state-of-the-art
interviewing, examination and laboratory methods.
The Third National Health and Nutrition Examination
Survey (NHANES III) was conducted in 1988-1994 on a
nationwide multi-stage probability sample of 39,695 per-
sons from the civilian, non-institutionalized population
aged 2 months and over of the United States. Persons
aged 60 and over, African Americans, and Mexican
Americans were oversampled. Details of the plan, sam-
pling, operation, response and institutional review board
approval have been published as have procedures used
to obtain informed consent and to maintain confidenti-
ality of information obtained [10]. The personal inter-
views and physical and laboratory examinations of
NHANES III subjects provided the baseline data for the
study. This analysis was based on the public-use version
of the NHANES III linked-mortality file with mortality
data through 2000. Of 33,994 persons with baseline
interview data, 13,944 were under age 17 and 26 lacked
data for matching leaving 20,024 eligible for mortality
follow-up. The NHANES III linked mortality file con-
tains information based upon the results from a
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NCHS National Death Index records. The NHANES III
linked mortality file provides mortality follow-up data
from the date of NHANES III survey participation
(1988-1994) through December 31, 2000.
Of the 20,022 interviewed persons with mortality fol-
low-up, 6588 were aged 60 years and over and eligible
to have cognitive function testing performed, 6339 of
whom had valid cognitive function data. After excluding
persons with missing data for any of the variables
shown in the tables, 4,911 persons aged 60 and over
with complete data remained for mortality analyses. The
length of follow-up of survivors ranged from 75 to 146
months, mean 108 months, median 107 months.
HDL. Serum lipids were measured at the Centers for
Disease Control and Prevention in Atlanta, Georgia.
HDL was measured in serum following the precipitation
of other lipoproteins with a polyanion/divalent cation
mixture. For descriptive analysis, quartiles of HDL con-
centration were formed. For regression analysis, persons
with concentrations below 40 mg/dL were compared to
those with 40 mg/dL and greater.
Cognitive Function. Questions assessing mental cogni-
tion were asked only of respondents aged 60 or older
and not to proxy respondents. These questionnaires
were designed for administration in a bilingual (English/
Spanish) format so that respondents could be inter-
viewed in their preferred language. The neuropsycholo-
gical measures used in the NHANES III study, were
selected to assess dimensions of cognitive function typi-
cally affected in dementia. A short cognitive function
index (SICF) was constructed for this analysis from
these items administered at home interview and/or at a
Mobile Examination Center to assess orientation, recall
and attention [11,12]. A higher score indicates a higher
level of cognitive function compared to a lower score.
Approximate quartiles were formed. For regression ana-
lysis, persons with scores below the median were com-
pared to those with scores above the median.
Estimates of the risk of death derive from Cox propor-
tional hazards regression models with time to event as
the time scale computed using the SURVIVAL proce-
dure in SUDAAN. Survivors were censored at the date
of the end of mortality follow-up. Logistic regression
models were also done to confirm key findings.
Table 1 shows characteristics of persons aged 60+ by
HDL level. In multivariate linear regression analyses,
HDL was not independently associated with SICF (not
shown). In proportional hazards regression models, per-
sons with a lower compared to a higher SICF score had
increased adjusted hazard of mortality (Table 2). Com-
pared to those with HDL >40 mg/dL those with HDL of
< = 40 mg/dL had increased adjusted hazard of mortal-
ity (Table 2). No significant interaction of SICF score
and HDL was detected (p = 0.08). However, a significant
interaction of age was seen with both SICF and HDL,
the adjusted effect of both on mortality increasing with
advancing age (Table 2). Table 2 shows fully adjusted
hazards ratios, indicating independent associations of
HDL and SICF score with survival, with strongest, sig-
nificant associations among the oldest persons. Much of
the association of HDL could be explained statistically
by controlling for physical activity level confirming its
likely causal association with both HDL level and
mortality.
This analysis of data from the NHANES III linked-
mortality file, a nation-wide representative sample,
tested for interaction of cognitive function and HDL as
predictors of survival in older Americans. Both low
HDL and poor cognitive function were found to inde-
pendently predict poor survival chances over follow-up.
However, no interaction of the two was detected. Effects
increased with age. However, a previously reported asso-
ciation between HDL and cognitive function could not
be replicated. The NHANES III provides population-
based data on the association of HDL, cognitive func-
tion, and survival in a nation-wide representative sample
Table 1 Prevalence (%) of selected characteristics by
quartile of high density lipoprotein cholesterol (HDL-C)
concentration in persons aged 60y and over (N = 4911)
HDL-C quartile
A l l 1234
Dead 32 36 31 28 31
Cognitive function index
<12 20 17 22 18 21
12-13 37 25 36 37 38
14-16 19 22 19 19 17
17 25 25 24 25 24
Female 57 34 53 64 79
Age 70+ 49 46 50 50 51
Mexican American 2 2322
African American 8 5781 1
South region 31 31 33 32 26
Metropolitan residence 44 41 46 39 48
Unmarried 40 30 36 43 50
Education < 12 y 41 46 41 40 36
Fair-poor health 28 34 31 22 25
≥1 chronic illness 56 62 57 54 51
Mobility limitation 33 33 35 31 33
Current smoking 15 16 14 15 14
Alcohol in past month 35 29 31 37 43
No regular physician 15 15 14 14 16
No religious attendance 12 10 12 14 12
Systolic BP ≥140 mmHg 51 50 51 54 47
BMI ≥30 kg/m2 23 29 27 22 15
No physical activity 79 79 78 81 77
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over permitted reliable estimates for this group. How-
ever, several unavoidable limitations of the present study
include possible bias arising from survey non-response
and missing values for some variables and from possible
changes in HDL and cognitive function and/or other
variables over the follow-up period. Adjusting for age,
HDL and SICF were also independently associated with
death in logistic regression models (p < 0.01) with no
significant interaction between them (p = 0.48). Further
longitudinal studies with measures of HDL subtypes,
apolipoprotein A-1, apoE, and multiple dimensions of
cognition and Alzheimer’s disease biomarkers would be
helpful.
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Table 2 Adjusted hazards ratios* of high density lipoprotein cholesterol, short index of cognitive function (SICF) for
survival in persons aged 60 years and over
All Age 60-69 Age 70-79 Age 80+
HR (95% CL)
HDL
< = 40 1.20 (0.99-1.46) 0.92 (0.67-1.27) 1.19 (0.87-1.64) 1.33 (1.12-1.58)**
>40 1.00 1.00 1.00 1.00
SICF
<13.6 1.09 (0.93-1.29) 1.11 (081-1.53) 1.10 (0.85-1.42) 1.32 (1.11-1.57)**
> = 13.6 1.00 1.00 1.00 1.00
N 1947 1442 915
*adjusted for age, gender, ethnicity, education, comorbidity, region, urbanization, health status, mobility, blood pressure, smoking, alcohol, physical activity.
**P < 0.01; +P < 0.05.
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